The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma.

ABSTRACT: The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are

SUBMITTER: Shaib WL 

PROVIDER: S-EPMC5126797 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature